{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T20:07:20Z","timestamp":1768421240756,"version":"3.49.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1097\/mol.0000000000000017","type":"journal-article","created":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T09:07:46Z","timestamp":1383296866000},"page":"475-479","source":"Crossref","is-referenced-by-count":25,"title":["Niacin"],"prefix":"10.1097","volume":"24","author":[{"given":"Henry N.","family":"Ginsberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gissette","family":"Reyes-Soffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20211004","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2796.2005.01528.x","article-title":"Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review.","volume":"258","author":"Carlson","year":"2005","journal-title":"J Int Med"},{"key":"R2-4-20211004","first-page":"360","article-title":"J Am Med A","volume":"231","year":"1975","journal-title":"ssoc"},{"key":"R3-4-20211004","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen-year mortality in coronary drug project patients: long-term benefit with niacin.","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"R4-4-20211004","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1001\/jama.1987.03390230069027","article-title":"Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.","volume":"257","author":"Blankenhorn","year":"1987","journal-title":"J Am Med Assoc"},{"key":"R5-4-20211004","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"key":"R6-4-20211004","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidants vitamins or the combination for the prevention of coronary disease.","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"R7-4-20211004","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER 2): a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"R8-4-20211004","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","article-title":"Extended-release niacin or ezetimibe and carotid intima-media thickness.","volume":"361","author":"Taylor","year":"2009","journal-title":"N Engl J Med"},{"key":"R9-4-20211004","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/MOL.0b013e3283613a68","article-title":"Recent advances in niacin and lipid metabolism.","volume":"24","author":"Kamanna","year":"2013","journal-title":"Curr Opin Lipidol"},{"key":"R10-4-20211004","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm824","article-title":"PUMA-G and HM74 are receptors for nicotinic acid and mediate its antilipolytic effect.","volume":"9","author":"Tunaru","year":"2003","journal-title":"Nat Med"},{"key":"R11-4-20211004","doi-asserted-by":"crossref","first-page":"9869","DOI":"10.1074\/jbc.M210695200","article-title":"Molecular identification of high and low affinity receptors for nicotinic acid.","volume":"278","author":"Wise","year":"2003","journal-title":"J Biol Chem"},{"key":"R12-4-20211004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.3003877","article-title":"Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.","volume":"4","author":"Lauring","year":"2012","journal-title":"Sci Transl Med"},{"key":"R13-4-20211004","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.amjmed.2012.03.017","article-title":"Extended-release niacin acutely suppresses postprandial triglyceridemia.","volume":"125","author":"Usman","year":"2012","journal-title":"Am J Med"},{"key":"R14-4-20211004","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.","volume":"365","author":"Investigators","year":"2011","journal-title":"N Engl J Med"},{"key":"R15-4-20211004","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/HCO.0b013e328362059d","article-title":"Recent clinical trials evaluating benefit of drug therapy for modification of HDL cholesterol.","volume":"28","author":"Wright","year":"2013","journal-title":"Curr Opin Cardiol"},{"key":"R16-4-20211004","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.jacc.2012.01.045","article-title":"Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDLHigh Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials.","volume":"59","author":"Michos","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R17-4-20211004","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study.","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"R18-4-20211004","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"2-THRIVEHPS2-Thrive randomized placebo-controlled trial in 25,673 high-risk patients on ER niacinlaropiprant; trial design, prespecified muscle and liver outcomes, and reasons for stopping study treatment.","volume":"34","author":"Collaborative Group","year":"2013","journal-title":"Eur Heart J"},{"key":"R19-4-20211004","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1161\/ATVBAHA.110.207142","article-title":"Cholesterol efflux potential and anti-inflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.","volume":"30","author":"Yvan-Charvet","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R20-4-20211004","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.amjcard.2003.10.009","article-title":"Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol: The HDL Atherosclerosis Treatment Study.","volume":"93","author":"Zhao","year":"2003","journal-title":"Am J Cardiol"},{"key":"R21-4-20211004","doi-asserted-by":"crossref","first-page":"562","DOI":"10.2337\/diab.38.5.562","article-title":"Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance.","volume":"38","author":"Kahn","year":"1989","journal-title":"Diabetes"},{"key":"R22-4-20211004","first-page":"1563","article-title":"ACCORD Study Groupfor the ACCORD Study Group. Effects of combination lipid therapy on cardiovascular events in type 2 diabetes mellitus: the action to control cardiovascular risk in Diabetes Study Group.","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"R23-4-20211004","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1001\/jama.1990.03450230043027","article-title":"Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.","volume":"264","author":"Kane","year":"1990","journal-title":"J Am Med Assoc"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00041433-201312000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T08:00:30Z","timestamp":1633507230000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00041433-201312000-00004"}},"subtitle":["a long history, but a questionable future"],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000000017","relation":{},"ISSN":["0957-9672"],"issn-type":[{"value":"0957-9672","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}